Patent: 7,482,327
✉ Email this page to a colleague
Summary for Patent: 7,482,327
Title: | Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules |
Abstract: | The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation. |
Inventor(s): | Hagerty; David (Pennington, NJ), Rusnak; James (Newtown, PA) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 11/399,666 |
Patent Claims: | see list of patent claims |
Details for Patent 7,482,327
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2025-04-06 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2025-04-06 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2025-04-06 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2025-04-06 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2025-04-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |